Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study

Autor: Yea Yuan Chang, Shu-Chen Kuo, Pei Wen Chao, Yung Tai Chen
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Bacterial Diseases
Antitubercular Agents
Fibrate
Biochemistry
Geographical Locations
Cohort Studies
Outcome Assessment
Health Care
Medicine and Health Sciences
Hypolipidemic Agents
education.field_of_study
Multidisciplinary
Pharmaceutics
Incidence (epidemiology)
Incidence
Fibric Acids
Drugs
Middle Aged
Lipids
Actinobacteria
Infectious Diseases
Research Design
Cohort
Tuberculosis Diagnosis and Management
Medicine
Drug Therapy
Combination
Female
Cohort study
Research Article
medicine.medical_specialty
Tuberculosis
Statin
Asia
medicine.drug_class
Science
030106 microbiology
Population
Taiwan
Research and Analysis Methods
03 medical and health sciences
Drug Therapy
Diagnostic Medicine
Internal medicine
medicine
Humans
education
Tuberculosis
Pulmonary
Aged
Retrospective Studies
Pharmacology
Bacteria
business.industry
Statins
Organisms
Biology and Life Sciences
medicine.disease
Tropical Diseases
Clinical trial
030104 developmental biology
People and Places
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Mycobacterium Tuberculosis
Zdroj: PLoS ONE, Vol 14, Iss 1, p e0210479 (2019)
PLoS ONE
ISSN: 1932-6203
Popis: ObjectivesAnimal and ex vitro studies suggested lipid-lowering agents (LLAs) may be used as an adjunct to standard anti- tuberculosis (TB) treatment. No human study has been conducted to date. Using the Taiwan National Health Insurance Research Database (NHIRD), the current population-based cohort study sought to examine the association between use of LLAs and outcomes of patients with pulmonary TB receiving anti-TB treatment.MethodsUsing a NHIRD from 2003 to 2010, this population-based cohort study retrospectively examined the association between LLAs (statins or fibrates) and the outcomes of patients with pulmonary TB receiving anti-TB treatment.ResultsA total of 1452 adult patients newly diagnosed with pulmonary TB during the study period were identified and compared with 5808 matched patients. In the LAA cohort, 1258 received statin, and 295 received fibrate. Compared with patients who did not take LLA, patients who took oral LLAs had similar incidence of treatment completion at 9, 12, and 24 months.ConclusionsNeither statins nor fibrates provide clinical benefit superior to that achieved with standard anti-tuberculosis treatment. Future clinical trials should investigate the effects of statins and fibrates on short-course standard anti-TB therapy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje